The USFDA has withdrawn its approval for the lymphatic cancer drug umralisib by a US-based biotech company due to higher risks of death in patients treated with it. Umralisib got its accelerated approval in the US in February 2021 to treat adult patients with marginal zone lymphoma receiving prior therapy and for adult patients with follicular lymphoma.
On the basis of updated clinical trial data, it was found that the risks of treatment with umralisib outweigh its benefits. Amid ongoing safety issues, the sale of the drug and its application for expanded use in other lymphomas were also withdrawn.
